10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

LOH11CR2A Antibody (N-term) Blocking Peptide

Synthetic peptide
Catalog # BP8651a

Specification

LOH11CR2A Antibody (N-term) Blocking Peptide - Product Information

Primary Accession O00534

LOH11CR2A Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 4013

Other Names
von Willebrand factor A domain-containing protein 5A, Breast cancer suppressor candidate 1, BCSC-1, Loss of heterozygosity 11 chromosomal region 2 gene A protein, VWA5A, BCSC1, LOH11CR2A

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP8651a was selected from the N-term region of human LOH11CR2A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LOH11CR2A Antibody (N-term) Blocking Peptide - Protein Information

Name VWA5A

Synonyms BCSC1, LOH11CR2A

Function
May play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis.

Tissue Location
Expressed at low level in many tissues. Not expressed in 80% of tumor cell lines tested

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

LOH11CR2A Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

LOH11CR2A Antibody (N-term) Blocking Peptide - Images

LOH11CR2A Antibody (N-term) Blocking Peptide - Background

LOH11CR2A may play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis.

LOH11CR2A Antibody (N-term) Blocking Peptide - References

Zhou,Y.Q., et.al., Cancer Sci. 100 (10), 1817-1822 (2009)